Results 181 to 190 of about 234,030 (235)

Lost and found in translation: the value of the human imiquimod model

British Journal of Clinical Pharmacology, EarlyView.
Topical imiquimod (IMQ), a Toll‐like receptor (TLR) 7 agonist, induces transient cutaneous inflammation and is widely used in preclinical research as a ‘psoriasis‐like’ mouse model. However, accumulating evidence indicates substantial divergence between IMQ‐driven biology and human plaque psoriasis pathogenesis.
Anouk C. Meijs, Juliette A. van den Noort, Salma Assil, Naomi B. Klarenbeek, Matthijs Moerland, Tessa Niemeyer‐van der Kolk, Robert Rissmann   +6 more
wiley   +1 more source

Prevalence of pregnancy and birth outcomes following biologic exposure in immune‐mediated inflammatory diseases: A population‐based study

British Journal of Clinical Pharmacology, EarlyView.
Aims Almost 5% of pregnancies are affected by immune‐mediated inflammatory diseases (IMIDs). As treatments become available, understanding their use during pregnancy is important. We aimed to describe maternal, pregnancy and infant outcomes among IMID pregnancies exposed to biologic therapies. Methods Using the Merative™ MarketScan® Commercial Database,
Leah K. Flatman, Lisiane F. Leal, Gabra Nohmie, Anick Bérard   +3 more
wiley   +1 more source

Surgical management of persistent gingival recession after sepsis‐associated gingival necrosis in a patient with systemic lupus erythematosus: A case report

Clinical Advances in Periodontics, EarlyView.
Abstract Background Sepsis‐associated gingival necrosis is an uncommon oral manifestation that may result in extensive gingival recession after the resolution of the acute phase. Methods This report presents the 2‐year follow‐up of periodontal management in a 38‐year‐old woman with systemic lupus erythematosus, who developed septic shock accompanied by
Risako Mikami, Koji Mizutani, Ruriko Mizuno, Yuji Kabasawa, Koichiro Matsuo   +4 more
wiley   +1 more source

Shared and Distinguishing Features of Late‐Onset Rheumatic Diseases Fulfilling Polymyalgia Rheumatica Classification Criteria

Arthritis &Rheumatology, EarlyView.
Kerem Abacar, Ala Altaie, Andrew Barr, Sarah L. Mackie, Kulveer Mankia, Dennis McGonagle   +5 more
wiley   +1 more source

Clinical Model‐Informed Precision Dosing Consult Service for Accelerating Personalized Medication in Pediatric Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who
Zachary L. Taylor, Takanobu Nadai, Kei Irie, Wen Rui Tan, Sanjana Parikh, Anhar Hosawi, Matthijs W. van Hoogdalem, Ronaldo Morales Junior, Sonya Tang Girdwood, Abbie D. Leino, Kana Mizuno, Alexander A. Vinks, Tomoyuki Mizuno   +12 more
wiley   +1 more source

<i>In Vivo</i> Dynamics of Immunoregulatory Lymphocyte Reconstitution: A Seven-year Longitudinal Study of Sustained Remission in Class IV Lupus Nephritis Following Rituximab Therapy. [PDF]

In Vivo
Hung SJ, Lu JW, Ho YJ, Lui SW, Hsieh TY, Jheng WL, Liu FC.   +6 more
europepmc   +1 more source

Training Opportunities Within the National Institute of Arthritis and Musculoskeletal and Skin Diseases

Arthritis &Rheumatology, EarlyView.
Janelle Hauserman, Isaah Vincent
wiley   +1 more source

Characterization of NAT2 Using Long‐Read Sequencing: Allele, Diplotype, and Phenotype Call Accuracy Compared to Other Testing Strategies

Clinical Pharmacology &Therapeutics, EarlyView.
The NAT2 pharmacogene is essential in drug metabolism, particularly for aromatic amines and hydrazines. Genetic variations in NAT2 categorize individuals as rapid, intermediate, or poor metabolizers based on their acetylation capacity to inform dosing guidelines.
Shobana John, Erin C. Boone, Byunggil Yoo, Laura B. Ramsey, Andrea Gaedigk   +4 more
wiley   +1 more source

Additional B-Lymphocyte Stimulator Inhibitors Treatment Facilitated Glucocorticoid Withdrawal in Lupus Nephritis Patients: A Real-World Retrospective Observational Single-Center Cohort Study. [PDF]

MedComm (2020)
Jin J, Tan M, Zhao M, Tan Y.
europepmc   +1 more source

A Pilot Randomized Study of NAT2 and YEATS4 Pharmacogenetic Return of Results in Adults with Hypertension and African Ancestry: The GUARDD‐US PGx Study

Clinical Pharmacology &Therapeutics, EarlyView.
Almost half of individuals with hypertension fail to achieve recommended blood pressure (BP) goals. Pharmacogenetic gene‐drug interactions may alter the efficacy of antihypertensive agents. We conducted a multicenter randomized controlled sub‐study of participants (N = 1874) with hypertension and self‐reported African ancestry to determine whether ...
Philip E. Empey, Nita A. Limdi, Dinushika Mohottige, Kady‐Ann Steen‐Burrell, Hrishikesh Chakraborty, Khoa A. Nguyen, Alexander S. Parker, Emily J. Cicali, Girish N. Nadkarni, Michelle A. Ramos, Sabrina Clermont, Erica N. Elwood, Mimsie Robinson, Nandini Shroff, Marc B. Rosenman, Ronald Huang, Larisa H. Cavallari, Julie A. Johnson, Paul R. Dexter, Todd C. Skaar, Kerri L. Cavanaugh, Christina M. Wyatt, Carol R. Horowitz, Rhonda M. Cooper‐DeHoff, Michael T. Eadon, on behalf of the IGNITE Pragmatic Trials Network   +25 more
wiley   +1 more source